Cargando…
Inhibitor clinical burden of disease: a comparative analysis of the CHESS data
BACKGROUND: Patients with hemophilia and inhibitors generally face greater disease burden compared to patients without inhibitors. While raising awareness of relative burden may improve the standard of care for patients with inhibitors, comparative data are sparse. Analyzing data drawn from the Cost...
Autores principales: | Oladapo, Abiola O., Lu, Mei, Walsh, Shaun, O’Hara, Jamie, Kauf, Teresa L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6230298/ https://www.ncbi.nlm.nih.gov/pubmed/30413215 http://dx.doi.org/10.1186/s13023-018-0929-9 |
Ejemplares similares
-
Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys
por: Burke, Tom, et al.
Publicado: (2021) -
The cost of severe haemophilia in Europe: the CHESS study
por: O’Hara, Jamie, et al.
Publicado: (2017) -
Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe
por: Burke, Tom, et al.
Publicado: (2021) -
Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study
por: Rodriguez-Santana, Idaira, et al.
Publicado: (2022) -
Relationship between bleeding episodes, health‐related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study
por: O'Hara, Jamie, et al.
Publicado: (2022)